Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.

Hair loss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hair follicles is considered a potential solution, but it's currently not feasible.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

The conversation discusses skepticism about new hair loss treatments, with many users expressing doubt about the effectiveness and availability of future solutions. Current treatments like minoxidil, finasteride, and hair transplants are mentioned as reliable options.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

Derma rollers may cause scarring alopecia, leading some to prefer dermastamps or dermapens for microneedling. Combining minoxidil with microneedling is effective, but proper technique and healing time are essential to prevent damage.

Dutasteride is more effective than finasteride for hair loss as it blocks more of the enzyme causing hair loss. New treatments like stem cell therapies and alternatives to minoxidil are being explored, but major advancements are still years away.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

A 23-year-old male experiencing worsening hair loss has tried topical Minoxidil, Finasteride, Progesterone, Hydrocortisone butyrate, and Ketoconazole. He is considering switching to oral Finasteride due to concerns about side effects and lack of improvement.

Finasteride and minoxidil are discussed as hair loss treatments, with mixed opinions on side effects like sexual dysfunction and mood changes. Some users report positive results, while others express concerns about potential risks and insufficient information.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

A user shared their progress in combating hair loss using 5 mg oral minoxidil and 1 mg finasteride over four months, experiencing significant improvement. They also experimented with higher doses of minoxidil but faced side effects, so they settled on 7.5 mg without issues.

A 24-year-old shared his 12-month hair loss progress, using 1mg oral finasteride daily, Minoxidil spray twice daily, weekly derma stamping, daily Biotin, Saw Palmetto Shampoo, and occasional Ketoconazole shampoo. He experienced minimal side effects and significant hair density improvement, no longer needing a hat.

Taking too much Zinc, around 30mg per day, might cause hair loss. The user is also using 0.5mg Dutasteride and 2.5mg Oral Minoxidil daily.

A user switched from a 1.5 mm derma roller to an adjustable dermastamp for microneedling to treat hair loss and found it less painful and more effective. Some users prefer different depths and tools like the Dr.Pen for microneedling, while others debate the necessity of depth and tool type.

RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.

Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.

Hair loss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.

Finasteride can cause sexual side effects, and reducing porn and masturbation may help improve sexual function. Some users experience persistent issues even after stopping finasteride.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.